Vericiguat

(Verquvo®)

Vericiguat

Drug updated on 5/17/2024

Dosage FormTablet (oral; 2.5 mg, 5 mg, 10 mg)
Drug ClassSoluble guanylate cyclase stimulators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Vericiguat (Verquvo) is indicated to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction below 45%.
  • Seven studies provided a comprehensive comparison of Vericiguat's safety and effectiveness against other heart failure management options.
  • Mixed results were observed in studies comparing Vericiguat to placebo regarding its ability to reduce cardiovascular death or heart failure hospitalization. However, in comparison with sacubitril/valsartan and sodium-glucose cotransporter 2 inhibitors, it was demonstrated that all these options could potentially decrease hospitalizations or deaths from cardiovascular causes in patients with reduced ejection fraction.
  • The safety profile of Vericiguat varies; common adverse effects include hypotension, syncope, and anemia. Similar rates for safety and efficacy endpoints were observed when compared with another sGC stimulator (riociguat), suggesting consistency within its class.
  • Subgroup analysis revealed that Vericiguat reduces risks associated with cardiovascular death and heart failure hospitalization in patients suffering from Heart Failure with Reduced Ejection Fraction (HFrEF), but does not show a therapeutic effect on Heart Failure with Preserved Ejection Fraction (HFpEF).
  • The effectiveness of Vericiguat across a broad spectrum of NT-proBNP levels up to 8000 pg/ml indicates its potential usefulness across various degrees of severity related to heart failures.